HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

AbstractPURPOSE:
Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.
PATIENTS AND METHODS:
We conducted a randomized, double-blind, controlled phase II trial in 83 patients who had just completed chemotherapy for relapsed ovarian cancer, with evidence of response, but at high risk of further early recurrence. The patients were randomly assigned to receive maintenance therapy using BIBF 1120 250 mg or placebo, twice per day, continuously for 36 weeks. End points were progression-free survival (PFS), toxicity, and overall survival.
RESULTS:
Thirty-six-week PFS rates were 16.3% and 5.0% in the BIBF 1120 and placebo groups, respectively (hazard ratio, 0.65; 95% CI, 0.42 to 1.02; P = .06). Four patients continued on BIBF 1120, including two patients for another year or more. The proportion of patients with any grade 3 or 4 adverse events was similar between the groups (34.9% for BIBF 1120 v 27.5% for placebo; P = .49; mostly grade 3). However, more patients on BIBF 1120 experienced diarrhea, nausea, or vomiting (mainly grade 1 or 2 and no grade 4). There was a higher rate of grade 3 or 4 hepatotoxicity in patients on BIBF 1120 (51.2%) compared with patients on placebo (7.5%; P < .001), but this was rarely of clinical significance, and patients continued with the trial treatment. A single-level dose reduction to 150 mg was made in 15 patients, all on active drug.
CONCLUSION:
BIBF 1120 is well tolerated and associated with a potential improvement in PFS. The observed treatment effect is sufficient to justify further study within a large phase III trial.
AuthorsJonathan A Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Iain McNeish, Helena Earl, Tim Perren, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay James, Graham Temple, Michael Merger, Gordon Rustin
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 29 Issue 28 Pg. 3798-804 (Oct 01 2011) ISSN: 1527-7755 [Electronic] United States
PMID21859991 (Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Angiogenesis Inhibitors
  • Indoles
  • Placebos
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • nintedanib
Topics
  • Adult
  • Aged
  • Angiogenesis Inhibitors (adverse effects, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Disease-Free Survival
  • Double-Blind Method
  • Female
  • Humans
  • Indoles (administration & dosage, adverse effects, therapeutic use)
  • Maintenance Chemotherapy
  • Middle Aged
  • Neoplasm Recurrence, Local (blood supply, drug therapy, enzymology)
  • Ovarian Neoplasms (blood supply, drug therapy, enzymology)
  • Placebos
  • Protein Kinase Inhibitors (adverse effects, therapeutic use)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: